Registered number: 07285506
CONSOLIDATED
FOR THE YEAR ENDED 31 MARCH 2025
PHARMADENT HOLDINGS LIMITED
COMPANY INFORMATION
PHARMADENT HOLDINGS LIMITED
CONTENTS
PHARMADENT HOLDINGS LIMITED
GROUP STRATEGIC REPORT
FOR THE YEAR ENDED 31 MARCH 2025
The Company is the ultimate parent undertaking for the Group and its trading subsidiary companies are Pharmaceuticals Direct Limited, DHB Oral Healthcare Limited, Pharmadent Limited, Coombe KP Limited and Bemin Limited.
The results for the year ended 31 March 2025 and financial position of the Group at this date are as shown in the annexed financial statements.
The results for the year ended 31 March 2025 and financial position of the Group at this date are as shown in the annexed financial statements.
Across the Group the director has focused on achieving improved gross profitability and growth. Although industry trading conditions are difficult, management have focused on selling profitable lines of stock. Overall, gross profit margin for the Group has increased to 16.8% from 14%.
Administrative costs have decreased when compared to the prior year as there were a number of one off expenses that are not expected to recur. This has resulted in the total profit increasing from the prior years.The Director remains satisfied with the trading levels and profitability of the Group.
The director looks to continue with the core sales in the UK, but looks to explore the rest of Europe and the world.
Administrative costs have decreased when compared to the prior year as there were a number of one off expenses that are not expected to recur. This has resulted in the total profit increasing from the prior years.The Director remains satisfied with the trading levels and profitability of the Group.
The director looks to continue with the core sales in the UK, but looks to explore the rest of Europe and the world.
The principal risk identified by management are the regulatory changes within the pharmaceuticals environment, foreign currency fluctuations, price risk and with the Group's supply chain and customers. The director manages the price risk but monitoring stock levels carefully and adapting to the market. Equally the director monitors foreign currencies where applicable but the majority of transactions remain in sterling.
The director ensures that both credit risk and cash flow are constantly managed within the Group's activities. The Group have procedures in place with new customers and credit is granted and agreed in advance and monitored on a regular basis. The liquidity of the Group is monitored closely by the Director within the Holding company on behalf of the Group when it is reviewing the core trade of the Group along with various loans and investments.
Management understand the risk of falling behind product ranges and changes in the industry and aims to mitigate these risks. Performance is regularly reviewed at an overview level with the suppliers and principal clients. The Group continues to enhance the value of long-established clients by offering a quality service and aiming to meet their demands in a timely fashion.
The directors is aware of the Medicines and Healthcare products Regulatory Agency (MHRA) regulatory requirements that are paramount to the Group's continued activities. Tight restrictions remain in place on the import and export of goods and over counterfeit pharmaceuticals. Management are proactive in this area and consider the impact of regulatory changes and devised procedures to mitigate such risks and uncertainties.
The director ensures that both credit risk and cash flow are constantly managed within the Group's activities. The Group have procedures in place with new customers and credit is granted and agreed in advance and monitored on a regular basis. The liquidity of the Group is monitored closely by the Director within the Holding company on behalf of the Group when it is reviewing the core trade of the Group along with various loans and investments.
Management understand the risk of falling behind product ranges and changes in the industry and aims to mitigate these risks. Performance is regularly reviewed at an overview level with the suppliers and principal clients. The Group continues to enhance the value of long-established clients by offering a quality service and aiming to meet their demands in a timely fashion.
The directors is aware of the Medicines and Healthcare products Regulatory Agency (MHRA) regulatory requirements that are paramount to the Group's continued activities. Tight restrictions remain in place on the import and export of goods and over counterfeit pharmaceuticals. Management are proactive in this area and consider the impact of regulatory changes and devised procedures to mitigate such risks and uncertainties.
The director considers the key performance indicators for the Group to be those that communicate the financial
performance and strength of the company as a whole, these being turnover, gross margin, and operating profit.
The director manages stock levels actively with the market to ensure gross margins are strong to manage operating profit within the Group.
performance and strength of the company as a whole, these being turnover, gross margin, and operating profit.
The director manages stock levels actively with the market to ensure gross margins are strong to manage operating profit within the Group.
Page 1
PHARMADENT HOLDINGS LIMITED
GROUP STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
The directors consider other key performance indicators for the Group being delivery and logistics of their products. More product lines require temperature controlled transports and this is closely monitored by the Group.
Section 172 of the UK Companies Act 2006 requires a director of a company to act in the way he or she considers, in good faith, would be most likely to promote the success of the Group for the benefit of its members as a whole, and in doing so have regard (amongst other matters) to the factors listed in section 172.
The Group have their own codes of conduct which lists out principles and practices which need to be followed to ensure the success of the Group is achieveable.
The Director of the Group is part of the senior management team who is also director of all the companies included in the group accounts. They have involvement and oversight of the internal operations so they can form opinions and decisions to ensure changes are made on a timely basis to ensure the success of the Group.
The Group recognises the importance of staff development and retention to the ongoing sucess of the business's.
The Group considers its supplier relationships as crucial in the sucessful running of the Group. We continue to build strong relationships with existing and new suppliers which allows us to react quickly with the market changes.
The Group looks to build on its relationships with existing customers and generating new customers with its quality products and swift distribution.
The Group continues to monitor and review the effect the business's have on the community and wider environment and actively and this is described more in the Carbon Reporting section.
It is important for the Group to engage in good business to maximise Shareholder Wealth in the correct manner that promotes strong sustainable and sucessful trading.
The Group have their own codes of conduct which lists out principles and practices which need to be followed to ensure the success of the Group is achieveable.
The Director of the Group is part of the senior management team who is also director of all the companies included in the group accounts. They have involvement and oversight of the internal operations so they can form opinions and decisions to ensure changes are made on a timely basis to ensure the success of the Group.
The Group recognises the importance of staff development and retention to the ongoing sucess of the business's.
The Group considers its supplier relationships as crucial in the sucessful running of the Group. We continue to build strong relationships with existing and new suppliers which allows us to react quickly with the market changes.
The Group looks to build on its relationships with existing customers and generating new customers with its quality products and swift distribution.
The Group continues to monitor and review the effect the business's have on the community and wider environment and actively and this is described more in the Carbon Reporting section.
It is important for the Group to engage in good business to maximise Shareholder Wealth in the correct manner that promotes strong sustainable and sucessful trading.
This report was approved by the board on 31 December 2025 and signed on its behalf.
Page 2
PHARMADENT HOLDINGS LIMITED
DIRECTOR'S REPORT
FOR THE YEAR ENDED 31 MARCH 2025
The director presents his report and the financial statements for the year ended 31 March 2025.
The profit for the year, after taxation and minority interests, amounted to £998,500 (2024 - £970,260).
No dividends were issued during the year by the entity (2024: £Nil).
The group has not paid any dividends to Non Controlling Interests outside the Group (2024: £364,350).
There are elements of the Director's report that have been included in the Strategic report.
The group has not paid any dividends to Non Controlling Interests outside the Group (2024: £364,350).
There are elements of the Director's report that have been included in the Strategic report.
The director who served during the year was:
Page 3
PHARMADENT HOLDINGS LIMITED
DIRECTOR'S REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
Carbon Neutral Britain was engaged by the Group in order to measure and calculate the organisations total carbon footprint for 2025/2024, with the purpose of offsetting and becoming Carbon Neutral. The Group looks to review, manage and monitor ways to reduce its energy efficiency moving forward.
The parent company falls below the threshold to report.
As a specialistin the procurement, storage and distribution of pharmaceutical and healthcare products, itwas identified that the main emissions were to occur from total organisation energy usageon site within the reporting period..
Scope 1 refers to Direct Emissions and Scope 2 being Indirect.
The parent company falls below the threshold to report.
As a specialistin the procurement, storage and distribution of pharmaceutical and healthcare products, itwas identified that the main emissions were to occur from total organisation energy usageon site within the reporting period..
Scope 1 refers to Direct Emissions and Scope 2 being Indirect.
The Group's greenhouse gas emissions and energy consumption for the year are totaling to 50.01 tCO2e
The period covered by this report is 1 January 2024 to 31 December 2024.
Page 4
PHARMADENT HOLDINGS LIMITED
DIRECTOR'S REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
For the comparative period (March 2024 accounts). The total was 17,744 kg CO2e for Scope 1 and 52,012 kg CO2e for Scope 2.
The total carbon footprint for March 2025 accounts was 50.01 tCO2e and for March 2024 accounts this was 70.61 tCO2e. Following the Baseline (first year) assessment of the organisation, Pharmaceuticals Direct
The total carbon footprint for March 2025 accounts was 50.01 tCO2e and for March 2024 accounts this was 70.61 tCO2e. Following the Baseline (first year) assessment of the organisation, Pharmaceuticals Direct
Ltd has seen/achieved a 29.18% reduction in overall emissions in year 2024. Based on these totals, the estimated kWH comparison for March 2025 accounts would be 217,000 kWH with the comparative year for March 2024 accounts being 251,000 kWH.
Year-on-Year Emissions by Source
A year-on-year analysis highlights the following three largest avoidable emission sources:
Year-on-Year Emissions by Source
A year-on-year analysis highlights the following three largest avoidable emission sources:
Energy Usage on Site has seen a 15% reduction from 52.01 tCO2e to 44.42 tCO2e
Mains Gas has seen a 85% reduction from 17.74 tCO2e to 2.74 tCO2e
Company Vehicles has seen a 179% increase from 0.86 tCO2e to 2.38 tCO2e
Intensity Ratio
2025 2024
Total tonnes of CO2 per employee (Scope 1) 0.079 0.326
Total tonnes of CO2 per employee (Scope 2) 0.691 0.913
Methodology used in calculation of disclosures
The Group's greenhouse gas emissions and energy consumption for the year are as per the table above. The methodology used to calculate this is GHG Protocol.
Intensity Ratio
2025 2024
Total tonnes of CO2 per employee (Scope 1) 0.079 0.326
Total tonnes of CO2 per employee (Scope 2) 0.691 0.913
Methodology used in calculation of disclosures
The Group's greenhouse gas emissions and energy consumption for the year are as per the table above. The methodology used to calculate this is GHG Protocol.
The auditors, Haslers, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006.
This report was approved by the board on 31 December 2025 and signed on its behalf.
Page 5
PHARMADENT HOLDINGS LIMITED
DIRECTOR'S RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 MARCH 2025
The director is responsible for preparing the Group Strategic Report, the Director's Report and the consolidated financial statements in accordance with applicable law and regulations.
Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the director must not approve the financial statements unless he is satisfied that they give a true and fair view of the state of affairs of the Company and the Group and of the profit or loss of the Group for that period.
In preparing these financial statements, the director is required to:
∙select suitable accounting policies for the Group's financial statements and then apply them consistently;
∙make judgments and accounting estimates that are reasonable and prudent;
∙state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
∙prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business.
The director is responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and the Group and to enable him to ensure that the financial statements comply with the Companies Act 2006. He is also responsible for safeguarding the assets of the Company and the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Page 6
PHARMADENT HOLDINGS LIMITED
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF PHARMADENT HOLDINGS LIMITED
We have audited the financial statements of Pharmadent Holdings Limited (the 'Parent Company') and its subsidiaries (the 'Group') for the year ended 31 March 2025, which comprise the Consolidated Statement of Comprehensive Income, the Consolidated Analysis of Net Debt, the Consolidated Balance Sheet, the Company Balance Sheet, the Consolidated Statement of Cash Flows, the Consolidated Statement of Changes in Equity, the Company Statement of Changes in Equity and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).
In auditing the financial statements, we have concluded that the director's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group's or the Parent Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the director with respect to going concern are described in the relevant sections of this report.
Page 7
PHARMADENT HOLDINGS LIMITED
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF PHARMADENT HOLDINGS LIMITED (CONTINUED)
The other information comprises the information included in the Annual Report other than the financial statements and our Auditors' Report thereon. The director is responsible for the other information contained within the Annual Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
In our opinion, based on the work undertaken in the course of the audit:
∙the information given in the Group Strategic Report and the Director's Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
∙the Group Strategic Report and the Director's Report have been prepared in accordance with applicable legal requirements.
In the light of the knowledge and understanding of the Group and the Parent Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Group Strategic Report or the Director's Report.
Page 8
PHARMADENT HOLDINGS LIMITED
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF PHARMADENT HOLDINGS LIMITED (CONTINUED)
Page 9
PHARMADENT HOLDINGS LIMITED
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF PHARMADENT HOLDINGS LIMITED (CONTINUED)
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Group financial statements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:
We obtained an understanding of the legal and regulatory frameworks that are applicable to the entity and determined that the most significant are those that:
• had a direct effect on the determination of material amounts and disclosures in the financial statements. These include but are not limited to the Companies Act 2006, GDPR, employment and Health & Safety legislation and tax legislation, and
• do not have a direct effect on the financial statements but compliance with which may be fundamental to the company’s ability to operate or to avoid a material penalty. These include operational and employment laws and regulations including the Medicines & Healthcare Products Regulatory Agency (MHRA). health and safety regulations, environmental regulations and GDPR.
We obtained an understanding of how the group are complying with those legal and regulatory frameworks by inquiring with the director and management. These inquiries were corroborated by a review of licences issued by the MHRA and documentation summarising any inspections that took place. This was used to assess the extent of compliance with the relevant laws and regulations. We also reviewed the controls in place for management to detect any non-compliance with regulations within the pharmaceutical industry.
We discussed among the audit engagement team including relevant internal tax specialists, regarding the opportunities and incentives, including management override of controls, that may exist within the organisation for fraud and how and where fraud might occur in the financial statements. We also communicated the applicable laws and regulations throughout our team and remained alert to any indications of non-compliance throughout the audit.
The risk of management override of controls is the area where the financial statements were most susceptible to material misstatement due to fraud. In addition, the key principal risks related to the existence of inappropriate journal entries to impact the profit for the year and management bias in accounting estimates.
Procedures performed to address these were as follows:
• Walkthrough testing was carried out to identify and assess the design effectiveness of controls, management have in place to prevent and detect fraud, including known of suspected instances or non- compliance with laws and regulations and fraud,
• Understanding how those charged with governance considered and addressed the potential for override of controls or other inappropriate influence over the financial reporting process,
• Using analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatements due to fraud,
Page 10
PHARMADENT HOLDINGS LIMITED
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF PHARMADENT HOLDINGS LIMITED (CONTINUED)
• Assessing the appropriateness of accounting estimates, such as stock provisions, and challenging any significant assumptions or judgements made by management,
• Incorporating testing of manual journal entries that were posted throughout the year. In particular, we focused on material journal entries, journal entries posted with unusual account combinations, as well as journal entries crediting revenue or cash. These were scrutinised for evidence of unusual entries,
• Selecting specific revenue transactions based on risk criteria and obtaining supporting documentation including sales invoice to ensure revenue was appropriately recorded,
• Reviewing specific cost of sale transactions based on risk criteria and reviewing invoice documentation to ensure the expense was appropriately recorded,
• Evaluated the business rationale of any significant transactions that are unusual or outside the normal course of business.
Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.
A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' Report.
Page 11
PHARMADENT HOLDINGS LIMITED
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF PHARMADENT HOLDINGS LIMITED (CONTINUED)
This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an Auditors' Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed.
for and on behalf of
Chartered Accountants
Statutory Auditor
Old Station Road
Essex
IG10 4PL
Page 12
PHARMADENT HOLDINGS LIMITED
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 MARCH 2025
Page 13
PHARMADENT HOLDINGS LIMITED
REGISTERED NUMBER: 07285506
CONSOLIDATED BALANCE SHEET
AS AT 31 MARCH 2025
Page 14
PHARMADENT HOLDINGS LIMITED
REGISTERED NUMBER: 07285506
CONSOLIDATED BALANCE SHEET (CONTINUED)
AS AT 31 MARCH 2025
The financial statements were approved and authorised for issue by the board and were signed on its behalf on 31 December 2025.
The notes on pages 22 to 44 form part of these financial statements.
Page 15
PHARMADENT HOLDINGS LIMITED
REGISTERED NUMBER: 07285506
COMPANY BALANCE SHEET
AS AT 31 MARCH 2025
The financial statements were approved and authorised for issue by the board and were signed on its behalf on 31 December 2025 .
The notes on pages 22 to 44 form part of these financial statements.
Page 16